Labeler
Accord Healthcare Inc. NDC Codes
Accord Healthcare Inc. lists 227 finished drug products in the FDA NDC Directory under NDC labeler code 16729.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Levothyroxine sodium, Lenalidomide, lurasidone hydrochloride, Hydroxychloroquine Sulfate, Glycopyrrolate, Tadalafil, Vilazodone Hydrochloride, Pemetrexed, Atropine Sulfate, Furosemide, Methylphenidate Hydrochloride, Olmesartan Medoxomil And Hydrochlorothiazide, Diltiazem Hydrochloride, Dofetilide, Cinacalcet
- Active ingredients
- Levothyroxine sodium, Lenalidomide, Lurasidone hydrochloride, Hydroxychloroquine sulfate, Glycopyrrolate, Tadalafil, Vilazodone hydrochloride, Pemetrexed disodium hemipentahydrate, Atropine sulfate, Furosemide, Methylphenidate hydrochloride, Olmesartan medoxomil
- NDC labeler codes
- 16729
- Strengths (from the 100 most recently listed products)
- Glycopyrrolate .2 mg/mL; Furosemide 10 mg/mL; Hydrochlorothiazide 12.5 mg/1; Olmesartan medoxomil 40 mg/1; Sugammadex sodium 200 mg/2mL; Sugammadex sodium 500 mg/5mL; Lenalidomide 2.5 mg/1; Lenalidomide 25 mg/1; Lenalidomide 15 mg/1; Lenalidomide 5 mg/1; Lenalidomide 20 mg/1; Lenalidomide 10 mg/1; Clomiphene citrate 50 mg/1; Alcohol 1 mL/mL; Teriflunomide 7 mg/1; Teriflunomide 14 mg/1; Regadenoson .08 mg/mL; Lurasidone hydrochloride 20 mg/1; Lurasidone hydrochloride 40 mg/1; Lurasidone hydrochloride 60 mg/1
- Dosage forms
- Tablet, Tablet, Film coated, Injection, Capsule, Injection, Powder, Lyophilized, For solution, Injection, Solution, Tablet, Extended release, Capsule, Extended release, Capsule, Delayed release, Ointment, Cream
- Routes
- Oral, Intravenous, Intramuscular, Topical, Subcutaneous, Sublingual, Percutaneous, Endotracheal, Intramedullary
- Drug classes (FDA established)
- l-Thyroxine, Atypical Antipsychotic, Anticholinergic, Cholinergic Muscarinic Antagonist, Thalidomide Analog, Folate Analog Metabolic Inhibitor, Antimalarial, Antirheumatic Agent, Phosphodiesterase 5 Inhibitor, Alkylating Drug, Loop Diuretic, Central Nervous System Stimulant, Angiotensin 2 Receptor Blocker, Thiazide Diuretic, Calcium Channel Blocker, Antiarrhythmic, Calcium-sensing Receptor Agonist, Pyrimidine Synthesis Inhibitor, Pyridone, Nucleoside Metabolic Inhibitor, Anti-coagulant, Direct Thrombin Inhibitor, Opioid Antagonist, Partial Opioid Agonist, Lipopeptide Antibacterial, Calcineurin Inhibitor Immunosuppressant, Aminoketone, P2Y12 Platelet Inhibitor, Estrogen Agonist/Antagonist, Pharmacologic Cardiac Stress Test Agent, Sphingosine 1-phosphate Receptor Modulator, Carbonic Anhydrase Inhibitor, Estrogen Receptor Antagonist, Topoisomerase Inhibitor, Dietary Cholesterol Absorption Inhibitor, Serotonin Reuptake Inhibitor
- HCPCS / J-code
- None in Med-Code's directory for these products
- Package NDCs
- 137 (from the 100 most recently listed products)
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Levothyroxine sodium | Levothyroxine sodium 300 ug/1 | TabletOral | 16729-458 | 16729-0458-15 | — |
| Glycopyrrolate | Glycopyrrolate .2 mg/mL | InjectionIntramuscular, Intravenous | 16729-472 | 16729-0472-08 | — |
| Glycopyrrolate | Glycopyrrolate .2 mg/mL | InjectionIntramuscular, Intravenous | 16729-473 | 16729-0473-03 | — |
| Glycopyrrolate | Glycopyrrolate .2 mg/mL | InjectionIntramuscular, Intravenous | 16729-474 | 16729-0474-03 | — |
| Levothyroxine sodium | Levothyroxine sodium 125 ug/1 | TabletOral | 16729-453 | 16729-0453-1516729-0453-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 175 ug/1 | TabletOral | 16729-456 | 16729-0456-1516729-0456-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 200 ug/1 | TabletOral | 16729-457 | 16729-0457-1516729-0457-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 50 ug/1 | TabletOral | 16729-448 | 16729-0448-1516729-0448-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 75 ug/1 | TabletOral | 16729-449 | 16729-0449-1516729-0449-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 88 ug/1 | TabletOral | 16729-450 | 16729-0450-1516729-0450-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 112 ug/1 | TabletOral | 16729-452 | 16729-0452-1516729-0452-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 137 ug/1 | TabletOral | 16729-454 | 16729-0454-1516729-0454-17 | — |
| Levothyroxine sodium | Levothyroxine sodium 150 ug/1 | TabletOral | 16729-455 | 16729-0455-1516729-0455-17 | — |
| Olmesartan Medoxomil And Hydrochlorothiazide | Olmesartan medoxomil 20 mg/1; Hydrochlorothiazide 12.5 mg/1 | Tablet, Film coatedOral | 16729-366 | 16729-0366-15 | — |
| Diltiazem Hydrochloride | Diltiazem hydrochloride 120 mg/1 | Capsule, Extended releaseOral | 16729-303 | 16729-0303-0116729-0303-16 | — |
| Diltiazem Hydrochloride | Diltiazem hydrochloride 180 mg/1 | Capsule, Extended releaseOral | 16729-304 | 16729-0304-0116729-0304-16 | — |
| Diltiazem Hydrochloride | Diltiazem hydrochloride 240 mg/1 | Capsule, Extended releaseOral | 16729-305 | 16729-0305-0116729-0305-16 | — |
| Olmesartan Medoxomil And Hydrochlorothiazide | Olmesartan medoxomil 40 mg/1; Hydrochlorothiazide 12.5 mg/1 | Tablet, Film coatedOral | 16729-367 | 16729-0367-15 | — |
| Olmesartan Medoxomil And Hydrochlorothiazide | Olmesartan medoxomil 40 mg/1; Hydrochlorothiazide 25 mg/1 | Tablet, Film coatedOral | 16729-368 | 16729-0368-15 | — |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | Buprenorphine hydrochloride 2 mg/1; Naloxone hydrochloride dihydrate .5 mg/1 | TabletSublingual | 16729-549 | 16729-0549-10 | — |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | Buprenorphine hydrochloride 8 mg/1; Naloxone hydrochloride dihydrate 2 mg/1 | TabletSublingual | 16729-550 | 16729-0550-10 | — |
| Methotrexate | Methotrexate sodium 2.5 mg/1 | TabletOral | 16729-486 | 16729-0486-01 | — |
| Dofetilide | Dofetilide .125 mg/1 | CapsuleOral | 16729-490 | 16729-0490-12 | — |
| Dofetilide | Dofetilide .25 mg/1 | CapsuleOral | 16729-491 | 16729-0491-12 | — |
| Dofetilide | Dofetilide .5 mg/1 | CapsuleOral | 16729-492 | 16729-0492-12 | — |
| Topotecan | Topotecan 1 mg/mL | InjectionIntravenous | 16729-243 | 16729-0243-31 | — |
| Cinacalcet | Cinacalcet hydrochloride 30 mg/1 | Tablet, Film coatedOral | 16729-440 | 16729-0440-1016729-0440-15 | — |
| Cinacalcet | Cinacalcet hydrochloride 60 mg/1 | Tablet, Film coatedOral | 16729-441 | 16729-0441-1016729-0441-15 | — |
| Cinacalcet | Cinacalcet hydrochloride 90 mg/1 | Tablet, Film coatedOral | 16729-442 | 16729-0442-1016729-0442-15 | — |
| Hydroxychloroquine Sulfate | Hydroxychloroquine sulfate 200 mg/1 | TabletOral | 16729-485 | 16729-0485-0116729-0485-16 | — |
| Tadalafil | Tadalafil 10 mg/1 | Tablet, Film coatedOral | 16729-371 | 16729-0371-1016729-0371-16 | — |
| Ezetimibe | Ezetimibe 10 mg/1 | TabletOral | 16729-433 | 16729-0433-10 | — |
| Busulfan | Busulfan 6 mg/mL | InjectionIntravenous | 16729-351 | 16729-0351-92 | — |
| Daptomycin | Daptomycin 350 mg/7mL | Injection, Powder, Lyophilized, For solutionIntravenous | 16729-434 | 16729-0434-0516729-0434-45 | — |
| Daptomycin | Daptomycin 500 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 16729-435 | 16729-0435-05 | — |
| Tacrolimus | Tacrolimus .3 mg/g | OintmentTopical | 16729-421 | 16729-0421-0116729-0421-1016729-0421-12 | — |
| Tacrolimus | Tacrolimus 1 mg/g | OintmentTopical | 16729-422 | 16729-0422-0116729-0422-1016729-0422-12 | — |
| Tadalafil | Tadalafil 2.5 mg/1 | Tablet, Film coatedOral | 16729-369 | 16729-0369-1016729-0369-16 | — |
| Tadalafil | Tadalafil 5 mg/1 | Tablet, Film coatedOral | 16729-370 | 16729-0370-1016729-0370-16 | — |
| Tadalafil | Tadalafil 20 mg/1 | Tablet, Film coatedOral | 16729-372 | 16729-0372-1016729-0372-16 | — |
| Bupropion Hydrochloride | Bupropion hydrochloride 300 mg/1 | Tablet, Extended releaseOral | 16729-444 | 16729-0444-1016729-0444-16 | — |
| Prasugrel | Prasugrel hydrochloride 5 mg/1 | Tablet, Film coatedOral | 16729-272 | 16729-0272-10 | — |
| Prasugrel | Prasugrel hydrochloride 10 mg/1 | Tablet, Film coatedOral | 16729-273 | 16729-0273-10 | — |
| Azacitidine | Azacitidine 100 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | 16729-306 | 16729-0306-10 | — |
| Quetiapine Fumarate | Quetiapine fumarate 200 mg/1 | Tablet, Extended releaseOral | 16729-095 | 16729-0095-12 | — |
| Quetiapine Fumarate | Quetiapine fumarate 300 mg/1 | Tablet, Extended releaseOral | 16729-096 | 16729-0096-12 | — |
| Quetiapine Fumarate | Quetiapine fumarate 150 mg/1 | Tablet, Extended releaseOral | 16729-109 | 16729-0109-12 | — |
| Bupropion Hydrochloride | Bupropion hydrochloride 150 mg/1 | Tablet, Extended releaseOral | 16729-443 | 16729-0443-1016729-0443-1516729-0443-16 | — |
| Bivalirudin | Bivalirudin 250 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | 16729-275 | 16729-0275-67 | — |
| Trazodone Hydrochloride | Trazodone hydrochloride 300 mg/1 | TabletOral | 16729-302 | 16729-0302-01 | — |
Accord Healthcare Inc.: common questions
- What is Accord Healthcare Inc.'s NDC labeler code?
- 16729. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Accord Healthcare Inc.?
- Med-Code's curated HCPCS directory has no drug-specific code for these products. Drugs dispensed by a pharmacy are billed by NDC. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.